Articles by Sam M

FarmaKeio Outsourcing is proud to announce the release of its latest innovation, the only patented hormone pellet with triamcinolone developed in an FDA-registered 503B outsourcing facility. The pellet is set to provide a new and revolutionary solution to hormone replacement therapy for men and women.

SOUTHLAKE, Texas, May 10, 2023 (Newswire.com)
–
FarmaKeio Outsourcing (FKO), a leading pharmaceutical outsourcing facility in the United States, has been granted a patent to produce testosterone and triamcinolone subcutaneous hormone pellets. The patent includes 23 claims, issued by the United States Patent and Trademark Office (USPTO), recognizing the company’s innovative approach to compounding hormone therapy and solidifying its position as a leader in the field of pharmaceutical development.

Unlike other hormone therapies, which may require frequent injections or daily pills, FarmaKeio Outsourcing’s hormone pellets provide a sustained release of testosterone and triamcinolone, allowing patients to enjoy the benefits of these hormones for extended periods of time. These pellets are inserted subcutaneously and gradually release the hormone over several months, reducing the need for frequent dosing and allowing patients to focus on their daily lives.

“We are thrilled to receive this patent for our subcutaneous hormone pellets,” said FarmaKeio Outsourcing’s CEO, Dan DeNeui. “Our team has worked tirelessly to develop this innovative approach to hormone therapy, and we are excited to be able to offer this option to patients in need.”

In addition to providing a more convenient method of hormone therapy, FarmaKeio’s pellets offer a unique formulation that is not available from any other FDA 503B registered outsourcing facility in the US. This proprietary formulation has been carefully designed and tested and it represents a significant breakthrough in the field of hormone therapy.

“We believe that our hormone pellets have the potential to revolutionize the way that hormone therapy is delivered,” said DeNeui. “By offering a sustained release of testosterone and triamcinolone, we can provide patients with a more consistent and reliable treatment option that can improve their quality of life.”

The issuance of this patent is a significant milestone for FarmaKeio Outsourcing, and it reflects the company’s ongoing commitment to innovation and excellence in pharmaceutical development. As the demand for hormone therapy continues to grow, FarmaKeio is well-positioned to meet the needs of patients and healthcare providers alike with its cutting-edge hormone pellets.

“We are confident that our hormone pellets will become the gold standard for hormone therapy, and we look forward to working with healthcare providers and patients to make this technology available to as many people as possible,” said Chief Operating Officer Cody Boatman.

The hormone pellet with triamcinolone is a groundbreaking new product that is set to revolutionize the hormone replacement therapy industry. With its unique combination of hormones and anti-inflammatory properties, it provides patients with a more comfortable treatment option. The pellet is an exclusive feature of The EvexiPEL Method, created and founded by Terri DeNeui, DNP, APRN, ACNP-BC, and is available exclusively through FarmaKeio Outsourcing, an FDA-registered 503B facility. With this new product, FarmaKeio Outsourcing is once again proving its commitment to providing innovative solutions to hormone replacement therapy.

About FarmaKeio Outsourcing 

FarmaKeio Outsourcing is a leading FDA-registered 503B pharmaceutical outsourcing facility that specializes in providing specific custom compounded medications to healthcare providers and facilities across the United States. FarmaKeio Outsourcing is committed to providing innovative, patient-centered solutions that meet the unique needs of their clients.

FarmaKeio Outsourcing offers an unwavering commitment to quality, safety, and compliance, operating a state-of-the-art facility that is cGMP compliant and undergoes rigorous testing and quality assurance procedures to ensure the highest level of quality and safety.

FarmaKeio Outsourcing provides exceptional customer service and support, ensuring that their clients have access to the resources and expertise necessary to make informed decisions about patient care. FarmaKeio Outsourcing is a trusted partner for healthcare providers looking to offer the most innovative and advanced care solutions to their patients.

Contact Information:

Danielle Tworek

Director of Marketing

[email protected]

5613253904

Original Source:

FarmaKeio Outsourcing Announces Patented Formulation of Revolutionary Hormone Therapy Pellet

The post FarmaKeio Outsourcing Announces Patented Formulation of Revolutionary Hormone Therapy Pellet first appeared on Enrose Magazine.

FarmaKeio Outsourcing is proud to announce the release of its latest innovation, the only patented hormone pellet with triamcinolone developed in an FDA-registered 503B outsourcing facility. The pellet is set to provide a new and revolutionary solution to hormone replacement therapy for men and women.

SOUTHLAKE, Texas, May 10, 2023 (Newswire.com)
–
FarmaKeio Outsourcing (FKO), a leading pharmaceutical outsourcing facility in the United States, has been granted a patent to produce testosterone and triamcinolone subcutaneous hormone pellets. The patent includes 23 claims, issued by the United States Patent and Trademark Office (USPTO), recognizing the company’s innovative approach to compounding hormone therapy and solidifying its position as a leader in the field of pharmaceutical development.

Unlike other hormone therapies, which may require frequent injections or daily pills, FarmaKeio Outsourcing’s hormone pellets provide a sustained release of testosterone and triamcinolone, allowing patients to enjoy the benefits of these hormones for extended periods of time. These pellets are inserted subcutaneously and gradually release the hormone over several months, reducing the need for frequent dosing and allowing patients to focus on their daily lives.

“We are thrilled to receive this patent for our subcutaneous hormone pellets,” said FarmaKeio Outsourcing’s CEO, Dan DeNeui. “Our team has worked tirelessly to develop this innovative approach to hormone therapy, and we are excited to be able to offer this option to patients in need.”

In addition to providing a more convenient method of hormone therapy, FarmaKeio’s pellets offer a unique formulation that is not available from any other FDA 503B registered outsourcing facility in the US. This proprietary formulation has been carefully designed and tested and it represents a significant breakthrough in the field of hormone therapy.

“We believe that our hormone pellets have the potential to revolutionize the way that hormone therapy is delivered,” said DeNeui. “By offering a sustained release of testosterone and triamcinolone, we can provide patients with a more consistent and reliable treatment option that can improve their quality of life.”

The issuance of this patent is a significant milestone for FarmaKeio Outsourcing, and it reflects the company’s ongoing commitment to innovation and excellence in pharmaceutical development. As the demand for hormone therapy continues to grow, FarmaKeio is well-positioned to meet the needs of patients and healthcare providers alike with its cutting-edge hormone pellets.

“We are confident that our hormone pellets will become the gold standard for hormone therapy, and we look forward to working with healthcare providers and patients to make this technology available to as many people as possible,” said Chief Operating Officer Cody Boatman.

The hormone pellet with triamcinolone is a groundbreaking new product that is set to revolutionize the hormone replacement therapy industry. With its unique combination of hormones and anti-inflammatory properties, it provides patients with a more comfortable treatment option. The pellet is an exclusive feature of The EvexiPEL Method, created and founded by Terri DeNeui, DNP, APRN, ACNP-BC, and is available exclusively through FarmaKeio Outsourcing, an FDA-registered 503B facility. With this new product, FarmaKeio Outsourcing is once again proving its commitment to providing innovative solutions to hormone replacement therapy.

About FarmaKeio Outsourcing 

FarmaKeio Outsourcing is a leading FDA-registered 503B pharmaceutical outsourcing facility that specializes in providing specific custom compounded medications to healthcare providers and facilities across the United States. FarmaKeio Outsourcing is committed to providing innovative, patient-centered solutions that meet the unique needs of their clients.

FarmaKeio Outsourcing offers an unwavering commitment to quality, safety, and compliance, operating a state-of-the-art facility that is cGMP compliant and undergoes rigorous testing and quality assurance procedures to ensure the highest level of quality and safety.

FarmaKeio Outsourcing provides exceptional customer service and support, ensuring that their clients have access to the resources and expertise necessary to make informed decisions about patient care. FarmaKeio Outsourcing is a trusted partner for healthcare providers looking to offer the most innovative and advanced care solutions to their patients.

Contact Information:

Danielle Tworek

Director of Marketing

[email protected]

5613253904

Original Source:

FarmaKeio Outsourcing Announces Patented Formulation of Revolutionary Hormone Therapy Pellet

The post FarmaKeio Outsourcing Announces Patented Formulation of Revolutionary Hormone Therapy Pellet first appeared on Enrose Magazine.

collaboratehealth® partners with MedBridge Healthcare to provide sleep apnea screening, diagnosis and therapy monitoring through their current technology platform.

…

The post collaboratehealth Announces Partnership With MedBridge Healthcare to Add Sleep Diagnostics to Their Hospital to Home 30-Day Readmission Reduction Program first appeared on Enrose Magazine.

Leading B2C Incontinence Care Brand Comes Together With Trusted Senior Advisory Service to Help Families Better Manage Incontinence Care

NorthShore…

The post NorthShore Partners With A Place for Mom to Support Caregivers and Bring Awareness to Premium Incontinence Products to Help Aging Loved Ones first appeared on Enrose Magazine.

Leading B2C Incontinence Care Brand Comes Together With Trusted Senior Advisory Service to Help Families Better Manage Incontinence Care

NorthShore…

The post NorthShore Partners With A Place for Mom to Support Caregivers and Bring Awareness to Premium Incontinence Products to Help Aging Loved Ones first appeared on Enrose Magazine.

Prominent Australian healthcare provider Northern Health joins the growing number of Agfa HealthCare customers in ASPAC, who are already leveraging the benefits of unified Enterprise Imaging platform. The agreement supports Northern Health’s vision to transform its healthcare services through outstanding innovations and excellence.

MELBOURNE, Australia, May 9, 2023 (Newswire.com)
–
Agfa HealthCare is pleased to announce that it has signed a five-plus-five-year agreement with Northern Health, in Melbourne, Australia. Agfa’s latest generation of the Enterprise Imaging 8.2 Platform for Radiology, including RUBEE^® for AI framework, will enhance the provider’s healthcare delivery capabilities. Enterprise Imaging innovations will bring “life in flow” to radiologists, and deliver advanced solutions, automation and efficient workflows which enables clinicians to stay focused on patient diagnosis and treatment.

Northern Health is a prominent public healthcare provider in Melbourne’s Northern Region, which is one of the fastest-growing communities in Australia. Established in 1998, Northern Health has become a vital part of the region’s healthcare ecosystem by delivering high-quality healthcare services to its diverse and rapidly growing population. The organization’s commitment to providing exceptional healthcare has led to the expansion of its services, which now include a broad range of specialist acute medical, surgical, maternity, sub-acute, and ambulatory health services across multiple locations, including Northern Hospital Epping, Broadmeadows Hospital, Craigieburn Centre, and the Bundoora Centre.

Northern Health joins the growing number of Australian healthcare providers, including Austin Health, Eastern Health, Adventist Healthcare and Sunshine Coast Hospital, who are already leveraging the benefits of the Agfa HealthCare Enterprise Imaging solution.

Enterprise Imaging innovations providing “life in flow” to Radiologists

“The choice of Agfa’s Enterprise Imaging platform aligns with our vision to deliver high-quality care and transform healthcare services through carefully considered investments in innovative technologies. Our strategic cooperation with Agfa HealthCare is a significant step forward in our quest to advance excellence in healthcare delivery in Melbourne’s North. Agfa HealthCare will provide advanced imaging IT functionalities, including AI clinical decision support to our Imaging program. We are delighted to take this first step in what we trust will be a long and beneficial relationship between Northern Health and Agfa HealthCare,” says Dr. Terry Kok, Director of Imaging for Northern Health.

“We are proud to partner with Northern Health in implementing our latest generation of the Enterprise Imaging platform that helps manage resource allocation, improve productivity, and provide clinical confidence with embedded AI capabilities. Today, radiologists face multiple pressure points and a constant demand to improve efficiencies of care delivery, while managing ever-greater volumes of incoming information. Our comprehensive medical imaging platform empowers radiologists to focus on patient care and confident diagnosis while increasing productivity and supporting their own well-being. In Agfa HealthCare we call it ‘Life in flow,'” says Jamie Osmond, Managing Director ASPAC for Agfa HealthCare.

“RUBEE^® for AI keeps radiologists in their flow while laying the foundation and framework for analytically intelligent ‘clinical packages’ seamlessly embedded within Agfa HealthCare Enterprise Imaging. By creating an efficient and effective work experience for radiologists, the Chest X-ray AI Analysis package powered by RUBEE^® and Lunit INSIGHT CXR will provide radiologists diagnostic confidence, optimize reading performance, and help improve productivity and overall delivery of patient care,” says Dr. Anjum Ahmed, Global Chief Medical Officer and Director Innovations for Agfa HealthCare.

Agfa’s Enterprise Imaging for Radiology is a comprehensive medical imaging platform that enables healthcare providers to capture, manage, store and distribute images and related data across the enterprise. Designed to support radiologists’ work at the top of their craft, its powerful automation features eliminate many of the menial tasks that stand in the way of doing more impactful work. The system is built to foster collaboration across departments, specialties, regions and time zones, so everyone can provide the best care to patients. 

Contact Information:

Agnieszka Kravic-Dubois

Marketing Communications

[email protected]

+32494561389

Miriam Ladin

Marketing and Communication Americas

[email protected]

+1 978 284 7777

Original Source:

Australian Northern Health Partners With Agfa HealthCare Enterprise Imaging and RUBEE for AI to Transform Healthcare Delivery

The post Australian Northern Health Partners With Agfa HealthCare Enterprise Imaging and RUBEE for AI to Transform Healthcare Delivery first appeared on Enrose Magazine.

SportGait’s Patented BKGTM Gait Technology Validated Through Peer-Reviewed Process for Mobile Phone Use and Published in The Journal of Pediatric Neuropsychology

WILMINGTON, N.C., May 9, 2023 (Newswire.com)
–
SportGait, the brain wellness and medical technology company helping to detect, track and prevent concussions, proudly announced today that its patented BKG™ gait technology has been validated for mobile phone use and published in the Journal of Pediatric Neuropsychology. This announcement comes on the heels of another peer-reviewed publication earlier this year in the Journal of Concussion that demonstrated BKG gait technology’s reliability and accuracy, proving that it can create biomarkers and be used to predict concussion outcomes effectively. The company is also in the process of validating the technology for use in Parkinson’s, Frailty, and other significant neurological conditions. 

The latest published study, Click Here, highlights that using a mobile device to perform SportGait’s BKG  gait test produced results equivalent to those produced when performing the gait test with dedicated body-worn sensors.  The study covers both adolescents and adults. Data also indicated that gait sensors can detect prolonged recovery trajectories for concussed patients. The mobile BKG scores were evaluated using more than 4,000 individuals and achieved strong test-retest reliability across all gait metrics. This outcome is truly groundbreaking for SportGait and the use of its technology in clinical practice. Putting SportGait’s unique clinically validated gait technology on a person’s mobile device allows for ubiquitous distribution and enables remote patient monitoring. Historically, a major barrier to easy and effective clinical treatment of concussions has been the need for multiple in-person assessments. SportGait’s mobile BKG test removes this barrier and enables remote patient monitoring and assessment without the need for in-person medical visits. 

“This new technology not only puts a powerful assessment tool in the hands of patients, but because it only takes 1-2 minutes to collect thousands of data points on gait, we are arming medical providers with considerable data to make more informed decisions,” says Dr. Len Lecci, lead researcher on the study.  

“Our goal at SportGait has always been to be able to provide efficient, efficacious, and economical tools and resources to help individuals, families, coaches and medical providers make more informed decisions around head injuries and concussions. By bringing our BKG  technology to the phone, we’re taking a major leap forward,” commented SportGait President and CEO Chris Newton. “Our newly updated mobile application will turn any smartphone into an incredibly powerful tool for assisting with clinical diagnosis and treatment plans for head injuries, without the costs and hassles that come with specialized sensors. That means fewer trips to the doctor without sacrificing quality of care.”

SportGait’s patented technology uses data collected by a mobile device’s accelerometers and creates BioKinetoGraphs (BKG), which are a visual depiction of a person’s gait. Similar to the shape of a waveform, the graph-like displays visually correspond to different events during a gait cycle such as the foot hitting the ground or pushing off of it. The company recently released version 2.0 of its software platform, which included an updated mobile application and enhanced communication through its ecosystem to support patients both in-clinic and remotely.

About SportGait

SportGait is a concussion support and recovery system that offers a scalable platform for medical providers, coaches, and parents. Their array of assessments are best-in-class and research-backed with the goal of bridging brain wellness with medical technology. The scientifically developed system aids and educates users in effectively evaluating and monitoring concussions. A scientific review of the system is Click Here.  SportGait is a highly trusted source of medical technology and was chosen to be the enterprise-wide standard for concussion testing for one of the top five largest hospital systems in the U.S. For more information please visit https://sportgait.com.

Contact Information:

Bethany Vietmeier

Marketing Manager

[email protected]

4127205195

Original Source:

Newly Vetted Gait Mobile Phone Technology Extends Biomarker Research and Clinical Access

The post Newly Vetted Gait Mobile Phone Technology Extends Biomarker Research and Clinical Access first appeared on Enrose Magazine.

Highly engaged employees say ‘caring’ is a key differentiator for virtual care company named on Inc.’s 2023 list of best U.S. workplaces.

CHICAGO, May 9, 2023 (Newswire.com)
–
First Stop Health (FSH), a leading virtual care company, has been named to Inc. Magazine’s annual list of Best Workplaces for a second year in a row. According to Inc., FSH employees are highly engaged because senior leadership values people as the most important resource. Overwhelmingly, employees described FSH’s work environment as caring. 

“All of us at FSH are striving towards providing delightful, affordable care,” said FSH CEO Teira Gunlock. “Uniting around that mission has created a foundation of mutual respect that every role is important. I’m thrilled this team is being recognized, again, for the caring FSH community we have built and I’m excited about our plans to further strengthen it and ensure it’s a place people love.”  

The Inc. Best Workplaces list is the result of a comprehensive measurement of American companies that have excelled in creating exceptional workplaces and company culture, whether operating in a physical or virtual facility. Each company that was nominated took part in an employee survey, conducted by Quantum Workplace, which included topics such as management effectiveness, perks, fostering employee growth, and overall company culture. The organization’s benefits were also audited to determine overall score and ranking.  

FSH has been named on an Inc. list for six years in a row, including 2018 through 2022, as one of the fastest-growing private companies on the Inc. 5000 list. The 2023 ranking for the Inc. 5000 list has not yet been announced. 

Here is what employees had to say about FSH in the Inc. Best Workplaces survey: 

“Working at First Stop Health is truly a pleasure. The culture, my coworkers and our mission are the best of any organization. My manager and leadership are incredibly dedicated to my professional and personal growth.” 

“I appreciate the transparency of the leadership team and feel like they do a great job keeping the entire organization updated. I am especially proud to make a difference in the healthcare sector. It’s an incredible feeling to get our members the health care they need, faster, more easily and for little-to-no cost.” 

“FSH exemplifies its pillars in the way we hire and the group of employees that make up our organization — caring, trusted, unrelenting and transparent. I have never worked in an organization with so many hardworking and caring individuals. They collaborate effectively, problem-solve across team lines, and support and encourage each other. Management is committed to open communication.” 

To learn more about First Stop Health, visit www.fshealth.com. 

About First Stop Health 

First Stop Health (FSH) provides care that people love with various digital healthcare services. Patients can access virtual care 24/7 via app, website or phone. We help them save time and money with safe, convenient, high-quality virtual care solutions — Primary Care, Urgent Care & Mental Health. FSH was named one of Inc. Magazine’s Best Workplaces of 2022 and 2023, and ranked one of the fastest-growing private companies for the past five years by Inc. 5000.

Contact Information:

Emily Kunisch

Senior Manager, Marketing

[email protected]

888-691-7867 x-410

Original Source:

First Stop Health Again Named One of Inc. Magazine’s Best Workplaces

The post First Stop Health Again Named One of Inc. Magazine’s Best Workplaces first appeared on Enrose Magazine.

MTM\/TCARE

LAKE SAINT LOUIS, Mo., May 9, 2023 (Newswire.com)
–
MTM, Inc., one of the nation’s leading non-emergency medical transportation (NEMT) broke…

The post MTM Invests in Aging in Place Technology Platform TCARE first appeared on Enrose Magazine.

The organization was named among the best workplaces in healthcare.

HOBOKEN, N.J., May 9, 2023 (Newswire.com)
–
Vytalize Health, a leading risk-bearing provider enablement platform, has been selected as one of Inc. magazine’s Best Workplaces for 2023. The list, which will be featured in the May/June issue and on Inc.com, is the result of a thorough evaluation of American companies that excel in establishing outstanding workplaces and company culture. 

“Being named to Best Workplaces is an honor that only a small fraction of companies have been able to claim,” says Inc. editor-in-chief Scott Omelianuk. “Proving to the world that you’re a magnet for talent and have a culture that keeps teams engaged, productive, and proud to come to work is a truly remarkable achievement.”

“We are honored to receive this recognition by Inc. magazine. At Vytalize Health, we are dedicated to fostering a culture that values inclusivity, empowerment, and a shared commitment to making a difference. We tackle significant challenges in our work to advance value-based care and always encourage collaboration and support among our employees. We believe that our sense of community and teamwork sets us apart as one of the best places to work,” said Faris Ghawi, Co-Founder and CEO.

In 2014, Faris Ghawi and Dr. Amer Alnajar co-founded Vytalize Health to improve healthcare quality and reduce the cost of care through a patient-centered, holistic care delivery model. The company’s all-in-one solution, including innovative incentives, smart technology, and a virtual and in-home clinic, empowers independent practices to succeed in value-based care arrangements and has transformed healthcare for hundreds of thousands of patients across the country.

With its ambitious vision of being the best facilitator of people’s healing through care that’s personalized, evidence-based, and kind, Vytalize Health is making strides by fostering a culture built on a foundation of principles that include transparency, reliability, and optimism. The Vytalize Health team is encouraged to ‘think big, but start small’ and to ‘hold itself to the highest standards’ to deliver an unparalleled healthcare experience for its patients. Vytalize Health aims to cultivate a space where its team of high performers feels they are doing their best work and making a sustainable impact on healthcare.

Recently, Vytalize Health closed a $100 million funding round to accelerate its mission of responsible value-based care. Additionally, the company acquired the Independent Physicians of Association of New York, one of the largest physician associations in the US.

About Vytalize Health
Vytalize Health is a risk-bearing provider enablement platform addressing the healthcare industry’s biggest challenges with its cutting-edge value-based care delivery system. Vytalize partners with more than 3,000 leading providers to improve the quality of care through evidence-based medicine and a patient experience rooted in kindness. By delivering the right data at the right time in the workflow to physicians and their staff, Vytalize makes its partners more efficient and effective, allowing them to focus on proactive, personalized medicine to improve the value of care and lower costs. Learn more at www.vytalizehealth.com.

Contact Information:

Matt Buder Shapiro

Chief Marketing Officer

[email protected]

+12163370461

Original Source:

Vytalize Health Recognized as a Top-Ranking Company on Inc. Magazine’s 2023 Best Workplaces List

The post Vytalize Health Recognized as a Top-Ranking Company on Inc. Magazine’s 2023 Best Workplaces List first appeared on Enrose Magazine.